Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cartesian Therapeutics (RNAC) Assets Average (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Assets Average for 10 consecutive years, with $334.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Assets Average fell 24.85% to $334.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $334.5 million, a 24.85% decrease, with the full-year FY2025 number at $365.7 million, down 1.17% from a year prior.
  • Assets Average was $334.5 million for Q4 2025 at Cartesian Therapeutics, down from $380.8 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $445.2 million in Q4 2024 to a low of $122.8 million in Q3 2023.
  • A 5-year average of $251.7 million and a median of $180.9 million in 2021 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: plummeted 32.97% in 2023, then skyrocketed 227.06% in 2024.
  • Cartesian Therapeutics' Assets Average stood at $163.5 million in 2021, then increased by 5.23% to $172.1 million in 2022, then increased by 19.45% to $205.5 million in 2023, then surged by 116.58% to $445.2 million in 2024, then fell by 24.85% to $334.5 million in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Assets Average are $334.5 million (Q4 2025), $380.8 million (Q3 2025), and $399.0 million (Q2 2025).